Group 1 - The core point of the article is that EasyRebio (SZ 300942) held its 12th meeting of the third board of directors on August 20, 2025, to discuss the proposal regarding the non-early redemption of "EasyRe convertible bonds" [1] - For the year 2024, EasyRebio's revenue composition is as follows: food rapid testing business accounts for 92.98%, animal disease testing accounts for 6.13%, and in vitro diagnostic business accounts for 0.89% [1] - As of the report date, EasyRebio's market capitalization is 5.3 billion yuan [2]